Pfizer Chairman and CEO Albert Bourla bought 38,000 shares in the open market on August 12, 2026, paying $26.34 per share for a total of about $1.00 million. Open-market purchases are closely watched because they typically involve an executive using personal funds to increase their ownership, rather than receiving shares through compensation or exercising options. Bourla’s role as both CEO and chairman makes the trade more notable than a purchase by a lower-level insider. As the top executive, he has broad visibility into Pfizer’s strategy, operations, and capital allocation, and his decision to add shares can be read as an alignment move with shareholders. Still, a $1.00 million buy is meaningful but small relative to Pfizer’s overall market value, so it’s best viewed as one data point rather than a standalone verdict on the business. Over the last 30 days, the only reported insider transaction provided is Bourla’s purchase. That means there isn’t enough disclosed activity here to confirm a broader “cluster” of insider buying from other executives or directors during early August, based on the listed records.